What is GLOW?
GLOW is a marketing name, not a scientific one, for a mix of three separate peptides. BPC-157 is a 15-amino-acid synthetic peptide based on part of a protein reported in human gastric juice. TB-500 is a synthetic peptide modeled on thymosin beta-4, usually a short fragment containing the part that binds actin. GHK-Cu is a three-amino-acid peptide found naturally in human plasma, bound to copper, and widely used in skin care.
The name seems to reflect the idea of repair inside and a healthy look outside. None of the three is an approved medicine, and they were developed and studied separately by different research groups. The amounts and exact forms of each part can differ between sources, especially for TB-500, where labels may not say whether it is the short fragment or the full protein.
How does GLOW work?
The reasoning for the blend is that each peptide appears to act through a different route in lab and animal studies. BPC-157 has been linked to new blood vessel growth through the VEGF pathway and to the nitric oxide system. Thymosin beta-4, the basis for TB-500, binds actin and has been linked to cell migration toward injured tissue and lower levels of some inflammatory signals. GHK-Cu delivers copper to cells and, in cell studies, increased collagen production and tissue remodeling.
In theory, these could cover different parts of the healing process. That is a hypothesis built from separate studies. No published research has tested what the three do together, whether they help or hinder each other, or how the combination affects safety.
What has research looked at?
- BPC-157
- Rat studies reported better healing of tendons, ligaments, muscle and gut lining. Human data are limited to a few small, uncontrolled reports.
- TB-500 and thymosin beta-4
- Full-length thymosin beta-4 was studied in animals for wounds, heart injury and hair, and in small human trials for skin ulcers and eye conditions, with mixed results. The TB-500 fragment itself has very little research.
- GHK-Cu
- Lab and animal studies reported more collagen and faster wound closure. Small cosmetic studies of GHK-Cu creams on facial skin reported modest improvements in some measures.
- The combination
- There are no published animal or human studies of these three peptides given together, by any route.
So the case for GLOW rests on three separate sets of research. The skin evidence comes mostly from GHK-Cu applied to the skin, not from injected blends. Claims about the blend as a whole go beyond what has been studied.
Side effects and cautions
No safety studies exist for the three-peptide blend. Each part has limited human safety data, and most of what is known comes from animals or from GHK-Cu applied to the skin. People often report stinging or burning where blends containing GHK-Cu were injected, along with redness, nausea, headache or tiredness, but these reports are anecdotal. Anyone with health questions should talk to a qualified clinician.
- Cancer history
- All three parts have been linked to blood vessel growth in lab or animal studies, and thymosin beta-4 to tumor spread in some lab work. That is a theoretical concern for people with current or past cancer.
- Copper
- GHK-Cu adds copper. People with conditions affecting copper handling, such as Wilson disease, face extra unknowns.
- Unknown interactions
- Combining three compounds can change effects in ways single-compound studies do not show.
- Product content
- Premixed blends may not match their labels in amount, purity or which form of TB-500 is inside.
- Pregnancy and breastfeeding
- There are no safety data for any of the three.
Further reading
This page summarizes the research in plain words. To read the studies yourself:
- Published studies on BPC-157 PubMed, US National Library of Medicine
- Published studies on thymosin beta-4, the protein TB-500 comes from PubMed, US National Library of Medicine
- Published studies on GHK-Cu PubMed, US National Library of Medicine
